{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"6"}]}],"title":"Any SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"11"}]}],"title":"Any AE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"11"}],"units":"Participants"}],"description":"Number of participants who experienced serious adverse events (SAE) and adverse events (AE).","groups":[{"description":"Dose escalation with rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"},{"description":"Dose expansion in TNBC participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG003","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG004","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG005","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG006","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG007","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG008","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received any study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to 2.32 years","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}